SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (5202)1/14/2002 9:52:05 AM
From: quidditch  Read Replies (1) of 52153
 
<KOSP> Obviously difficult to assess the potential patent and infringement issues, especially when it is not yet clear which company is asserting the right to market generic niaspan (if I have that right), but any thoughts here Peter as the market continues to mark Kos P down?

quid

PS At dinner Friday night, a friend who is an active inventor in tech of various types and who lives not far from the Charles River, in Gloucester--well, not too far--had not heard about the en banc decision and SC oral argument in Festo (his wife, who works in the media biz in NYC) had because of one of her pet right wing targets who argued the case, had). Thanks for the brief and article.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News